RNAZ (TransCode Therapeutics, Inc. Common Stock) Stock Analysis - AI Report
TransCode Therapeutics, Inc. Common Stock (RNAZ) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAZ trades at $6.35 with a market cap of $5.66M and a P/E ratio of -0.12. RNAZ moved +0.00% today. Year to date, RNAZ is -17.43%; over the trailing twelve months it is -25.12%. Its 52-week range spans $5.56 to $739.20. Rallies surfaces RNAZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on RNAZ?
Rallies AI research for RNAZ combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Fitzgerald Thomas A bought 49.35K (~$25.17K) on Sep 28, 2023.
Dudley Robert Michael bought 98.00K (~$49.98K) on Sep 28, 2023.
Dudley Robert Michael bought 12.00K (~$31.82K) on Jun 21, 2023.
RNAZ Analyst Consensus
RNAZ analyst coverage data. Average price target: $0.00.
Common questions about RNAZ
What is the AI research view on RNAZ?
Rallies AI research for RNAZ combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for RNAZ?
Rallies AI research for RNAZ combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is RNAZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAZ. It does not provide personalized investment advice.
